Journal article
Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis
Abstract
BACKGROUND: Sublingual immunotherapy with liquid extracts provides an appealing alternative to subcutaneous immunotherapy for the treatment of allergic rhinoconjunctivitis (ARC), but a lack of robust evidence has deterred its use in North America.
OBJECTIVE: To determine the efficacy and tolerability of standardized glycerinated short ragweed sublingual allergen immunotherapy liquid (RW-SAIL) extract in subjects with ragweed-related ARC.
Authors
Creticos PS; Esch RE; Couroux P; Gentile D; D'Angelo P; Whitlow B; Alexander M; Coyne TC
Journal
The Journal of Allergy and Clinical Immunology, Vol. 133, No. 3, pp. 751–758
Publisher
Elsevier
Publication Date
3 2014
DOI
10.1016/j.jaci.2013.10.041
ISSN
0091-6749